SEC Form DFiling only, no announcement found
NextPoint Therapeutics, based in Cambridge, MA, reported $33,728,772 sold in a private offering of equity and options or warrants, with the first sale on July 22, 2026, in a Form D filed with the SEC on July 30, 2026. The filing says 15 investors have already invested. The offering authorizes up to $48,729,165.
Legal name on the filing: NextPoint Therapeutics, Inc..
| Amount sold | $33,728,772Basis: Form D total amount sold, as of the filing of July 30, 2026. Not the announced round size. |
|---|---|
| Total offering | $48,729,165The most the company may sell under this offering. Not money raised. |
| Remaining to be sold | $15,000,393 |
| Securities offered | Equity; Option, warrant or other right to acquire another security |
| Exemption claimed | Rule 506(b) |
| Date of first sale | July 22, 2026 |
| Investors already invested | 15 |
| Non-accredited investors | None |
| Minimum investment accepted | $0 |
| Part of a merger or acquisition | No |
| Industry group | Biotechnology |
| Principal place of business | Cambridge, MA |
| Jurisdiction of incorporation | DELAWARE |
| Entity type | Corporation |
| Year of incorporation | over five years ago |
| Revenue range | Decline to Disclose |
| SEC CIK | 1959209 |
Round name, valuation, lead investor and participants are not on a Form D, so they are not shown. They appear here only when a press or company announcement is matched to this deal.
| Name, as filed | Relationship | VC Beast profile |
|---|---|---|
| Detlev Biniszkiewicz | Director | None linked |
| Ivan Cheung | Executive Officer, Director | None linked |
| Axel Hoos | Director | None linked |
| R. Jacob Vogelstein | Director | None linked |
| Brian Shuster | Director | None linked |
| Paulina Hill | Director | None linked |
| Rakhshita Dhar | Director | None linked |
| Jeffrey Lacey | Executive Officer | None linked |
Form D lists the company's executive officers, directors and promoters. A director is often an investor's board representative, but the filing does not say who invested.
| Filed | Form | Amount sold | Total offering |
|---|---|---|---|
| Jul 30, 2026 | D (original) | $33,728,772 | $48,729,165 |
The latest filing states the current amount sold; an amendment replaces the figure before it.
From the issuer's EDGAR filing history. Amounts are shown for filings in our warehouse, which holds operating-company filings from July 16, 2026.
Filing only, no announcement found. The only source for this deal is the company's own SEC filing, made under penalty of law. When a press or company announcement is matched to it, it is cited here with the round name it gives.
Amount sold is the filing's total amount sold; total offering is its authorized maximum. This page was built from filings received through September 29, 2026. Report an error on the corrections page.
Cite this deal
VC Beast, "NextPoint Therapeutics: SEC Form D deal record", https://vcbeast.com/deals/nextpoint-therapeutics-form-d-2026-07-22. Source: SEC EDGAR, accession 0001959209-26-000002.